摘要
目的评价培美曲塞联合顺铂治疗肺腺癌的临床疗效,为临床选择肺腺癌一线化疗方案提供循证证据。方法遵循Cochrane系统评价手册中随机对照试验检索策略,检索2005—2012年中国知网文献数据库中公开发表的关于培美曲塞联合顺铂治疗肺腺癌临床疗效的随机对照试验,对照组采用多西他赛联合顺铂方案,试验组采用培美曲塞联合顺铂方案。采用Jadad量表评价纳入文献的方法学质量,RevMan 5.0软件包进行数据分析。结果最终纳入8篇文献,Jadad量表评分均≥3分。Meta分析结果显示,试验组总有效率高于对照组〔OR=1.50,95%CI(1.01,2.21),P=0.04〕。结论培美曲塞联合顺铂方案治疗肺腺癌的总有效率高于多西他赛联合顺铂方案,可作为肺腺癌一线化疗方案。
Objective To evaluate the clinical effect of pemetrexed combined with cisplatin on lung adenocarcinoma,to provide evidence- based evidence of first- line chemotherapy regimens for lung adenocarcinoma. Methods Guided by the search strategy for randomized controlled trial（ RCT） of Cochrane Systematic Evaluation Handbook,literatures about effect of pemetrexed combined with cisplatin on lung adenocarcinoma were searched in CNKI from 2005 to 2012. control group given docetaxel combined with cisplatin,while experiment group given pemetrexed combined with cisplatin. Jadad scale was used to assess the methodological quality,RevMan 5. 0 software to analyze the data. Results A total of 8 literatures enrolled meta- analysis at last,all of the 8 literatures＇ scores of Jadad scale were equal or above 3. Meta- analysis result showed that,the total effective rate of experiment group was higher than that of control group 〔OR = 1. 50,95% CI（ 1. 01,2. 21）,P = 0. 04〕. Conclusion Pemetrexed combined with cisplatin has a higher total effective rate than docetaxel combined with cisplatin in treating lung adenocarcinoma,which can be used as the first- line chemotherapy regimens.
出处
《实用心脑肺血管病杂志》
2014年第10期13-15,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
腺癌
肺肿瘤
培美曲赛
顺铂
治疗结果
META分析
Adenocarcinoma
Lung neoplasms
Pemetrexed
Cisplatin
Treatment outcome
Meta-analysis
